You're using a free limited version of DrugPatentWatch: Upgrade for Complete Access

Last Updated: February 17, 2025

Drug Price Trends for SILODOSIN


✉ Email this page to a colleague

« Back to Dashboard


Drug Price Trends for SILODOSIN

Average Pharmacy Cost for SILODOSIN

These are average pharmacy acquisition costs (net of discounts) from a US national survey
Drug Name NDC Price/Unit ($) Unit Date
SILODOSIN 4 MG CAPSULE 72205-0009-30 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 59651-0095-30 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 69238-1421-03 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 27241-0144-01 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 68180-0740-06 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 31722-0635-30 0.39083 EACH 2025-01-22
SILODOSIN 4 MG CAPSULE 33342-0384-07 0.39083 EACH 2025-01-22
>Drug Name >NDC >Price/Unit ($) >Unit >Date

Best Wholesale Price for SILODOSIN

These are wholesale prices available to the US Federal Government which, by law, must be the best prices available to any customer under comparable terms and conditions
Drug Name Vendor NDC Count Price ($) Price/Unit ($) Unit Dates Price Type
SILODOSIN 4MG CAP,ORAL AvKare, LLC 42291-0777-30 30 154.60 5.15333 EACH 2023-06-15 - 2028-06-14 FSS
SILODOSIN 8MG CAP,ORAL AvKare, LLC 42291-0778-90 90 463.82 5.15356 EACH 2023-06-15 - 2028-06-14 FSS
>Drug Name >Vendor >NDC >Count >Price ($) >Price/Unit ($) >Unit >Dates >Price Type
Price type key: Federal Supply Schedule (FSS): generally available to all Federal Govt agencies / 'BIG4' prices: VA, DoD, Public Health & Coast Guard only / National Contracts (NC): Available to specific agencies

Market Analysis and Price Projections for Silodosin

Introduction to Silodosin

Silodosin is a selective alpha-1 adrenergic receptor antagonist primarily used in the treatment of benign prostatic hyperplasia (BPH). Its unique mechanism of action, which improves urinary flow with minimal side effects, has made it a preferred choice in therapeutic regimens for BPH[2].

Market Size and Growth Projections

The Silodosin market is anticipated to experience significant growth from 2024 to 2031. Here are some key points:

  • Compound Annual Growth Rate (CAGR): The market is expected to grow at a remarkable CAGR, driven by increasing demand for effective BPH treatments. This growth is attributed to the rising prevalence of BPH, particularly among the aging population[2][3].
  • Revenue Projections: The market is forecasted to generate substantial revenue, measured in USD million, across various segments. The forecast period from 2024 to 2031 is expected to see robust growth in market value[1][2].

Market Dynamics

The market dynamics of Silodosin are influenced by several factors:

  • Drivers:

    • Increasing Awareness: Rising awareness among healthcare professionals and patients about the benefits of Silodosin, such as its selective alpha-1 adrenergic receptor antagonism, is a significant driver. This specificity enhances patient compliance and positions Silodosin as a preferred treatment option[2].
    • Regulatory Support: Favorable reimbursement policies and regulatory support are propelling market growth. Governments are incentivizing the use of effective medications like Silodosin through reimbursement schemes, ensuring affordability for patients and encouraging healthcare providers to prescribe it more frequently[2].
    • Improving Healthcare Infrastructure: Emerging economies, especially in Asia-Pacific and Latin America, are investing in healthcare facilities and awareness campaigns, leading to increased adoption of Silodosin[2].
  • Restraints:

    • Patent Expirations: The entry of generic alternatives following patent expirations could lead to reduced profit margins for branded products. This poses a significant threat to revenue streams[2].
    • Regulatory Landscapes: Stringent regulatory landscapes governing pharmaceutical approvals can delay the introduction of new formulations or combinations[2].

Segmentation of the Market

The Silodosin market is segmented based on several key factors:

  • Type: The market is segmented into powder and solvent forms. Each form has its own set of applications and market dynamics[1].
  • Application: The primary applications are in hospitals and clinics. These settings drive the demand for Silodosin due to the high prevalence of BPH among the patient population[1].
  • Geography: The market is segmented geographically into North America, Europe, Asia-Pacific, South America, and the Middle East and Africa. The Asia-Pacific region is witnessing robust growth due to a rapidly aging demographic and increasing urbanization[1][2].

Competitive Landscape

The competitive landscape of the Silodosin market is dynamic, with several key players:

  • Key Players: Companies such as Kissei Pharmaceuticals Co Ltd, Cadila Healthcare Ltd, Hetero Drugs Ltd, and others are prominent in the market. These companies are involved in various market-related activities including product launches, mergers and acquisitions, and partnerships[2].
  • Research and Development: Efforts are directed towards exploring combination therapies that integrate Silodosin with other agents for a synergistic effect, potentially increasing its therapeutic efficacy and market share[2].

Geographical Performance

Geographically, the Silodosin market is performing well in various regions:

  • Asia-Pacific: This region is witnessing robust growth due to a rapidly aging demographic and increasing urbanization. Countries like Japan and China are experiencing a surge in BPH cases, prompting healthcare professionals to prescribe Silodosin more frequently[2].
  • Latin America: This region is gradually emerging as a significant player, driven by improving healthcare access and increased awareness of urological disorders. Brazil and Mexico are at the forefront, where healthcare reforms have enhanced the availability of medications[2].

Price Projections and Affordability

The cost of Silodosin can vary based on several factors, including the pharmacy and the presence of generic alternatives:

  • Current Pricing: The cost for Silodosin 8 mg oral capsules is around $43 for a supply of 30 capsules, depending on the pharmacy. Generic versions can be more affordable, with prices starting from $27.80 for 30 capsules of the 4 mg formulation[5].
  • Future Pricing Trends: As the market grows and more generic alternatives enter, prices may stabilize or decrease. However, the entry of new branded products or combination therapies could maintain or increase prices[2].

Challenges and Opportunities

Despite the positive outlook, the Silodosin market faces several challenges and opportunities:

  • Challenges:

    • Patent Expirations: The entry of generic alternatives poses a significant threat to revenue streams for branded products.
    • Regulatory Landscapes: Stringent regulatory landscapes can delay the introduction of new formulations or combinations[2].
  • Opportunities:

    • Emerging Markets: Regions with expanding healthcare infrastructures present a wealth of opportunities. The integration of telemedicine and digital health platforms facilitates patient engagement and timely diagnosis, boosting the demand for Silodosin capsules[2].

Forecasting Future Growth

The future growth of the Silodosin market is driven by several factors:

  • Increasing Geriatric Population: As the global population ages, the prevalence of BPH escalates, creating a robust demand for effective treatment options like Silodosin[2].
  • Patient-Centric Approaches: The global market is shifting towards patient-centric approaches, with healthcare providers focusing on personalized medicine that tailors treatment plans according to individual patient needs[2].

Clinical Efficacy and Safety

Clinical studies have demonstrated the efficacy and safety of Silodosin:

  • Post-Marketing Surveillance: A study conducted in Japan showed that switching to Silodosin from other alpha-1 blockers significantly improved symptoms associated with BPH. Silodosin was well tolerated, with an overall incidence of adverse drug reactions of 8.1% and no unexpected safety signals[4].

Key Takeaways

  • Robust Growth: The Silodosin market is expected to experience significant growth from 2024 to 2031, driven by increasing demand for effective BPH treatments.
  • Geographical Expansion: The Asia-Pacific and Latin America regions are key growth areas due to aging demographics and improving healthcare infrastructure.
  • Competitive Landscape: Key players are focusing on strategic partnerships, research and development, and the launch of new formulations.
  • Affordability: The entry of generic alternatives is expected to make Silodosin more affordable, although prices may vary based on the pharmacy and region.

FAQs

1. What is Silodosin used for? Silodosin is primarily used in the treatment of benign prostatic hyperplasia (BPH), a condition that affects the prostate gland in men.

2. What are the key drivers of the Silodosin market? Key drivers include increasing awareness of Silodosin's benefits, favorable reimbursement policies, and improving healthcare infrastructure in emerging economies.

3. Which regions are expected to drive the growth of the Silodosin market? The Asia-Pacific and Latin America regions are expected to drive growth due to their rapidly aging demographics and improving healthcare access.

4. How does Silodosin compare to other alpha-1 blockers in terms of efficacy and safety? Silodosin has been shown to be effective and safe in clinical studies, with significant improvements in symptoms associated with BPH and a low incidence of adverse drug reactions[4].

5. What is the current pricing for Silodosin, and how might it change in the future? The current pricing for Silodosin varies, with generic versions starting from around $27.80 for 30 capsules of the 4 mg formulation. Future pricing trends may stabilize or decrease with the entry of more generic alternatives, but could also be influenced by new branded products or combination therapies[5].

Sources

  1. Market Research Intellect: Global Silodosin Market Size, Scope And Forecast Report.
  2. Drug Patent Watch: Generic SILODOSIN INN entry, pharmaceutical patent expiry and market dynamics.
  3. QYResearch: Global Silodosin Capsules Market Insights, Forecast to 2030.
  4. PubMed: Post-Marketing Surveillance of Silodosin in Patients with Benign Prostatic Hyperplasia.
  5. Drugs.com: Silodosin Prices, Coupons, Copay Cards & Patient Assistance.

More… ↓

⤷  Try for Free

Make Better Decisions: Try a trial or see plans & pricing

Drugs may be covered by multiple patents or regulatory protections. All trademarks and applicant names are the property of their respective owners or licensors. Although great care is taken in the proper and correct provision of this service, thinkBiotech LLC does not accept any responsibility for possible consequences of errors or omissions in the provided data. The data presented herein is for information purposes only. There is no warranty that the data contained herein is error free. thinkBiotech performs no independent verification of facts as provided by public sources nor are attempts made to provide legal or investing advice. Any reliance on data provided herein is done solely at the discretion of the user. Users of this service are advised to seek professional advice and independent confirmation before considering acting on any of the provided information. thinkBiotech LLC reserves the right to amend, extend or withdraw any part or all of the offered service without notice.